Clinical trials: Neoadjuvant Chemoimmunotherapy
Non Small Cell Lung Cancer
A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC
To evaluate the efficacy and safety adebrelimab in Combination with chemotherapy after 3 cycles as neoadjuvant therapy and surgery or chemoradiotherapy based on MDT compared with adebrelimab after chemoradiotherapy in potentially…
- Trial name
- NCT06424899
- Testing
- Adebrelimab, radical chemoradiotherapy, Platinum based chemotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Zeng Jian
Lung Cancer
Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer
Predicting relapse and overall survival in potentially resectable Stage IIIA-IIIB Non-small Cell Lung Cancer (NSCLC) patients remains challenging.
- Trial name
- NCT06267144
- Testing
- Sintilimab plus chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Hospital of Jilin University
Cervical Cancer, Neoadjuvant Chemoimmunotherapy
Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer
This study is an exploratory clinical trial to investigate the feasibility of neoadjuvant chemoimmunotherapy plus extrafascial hysterectomy and pelvic lymph node dissection in patients with stage IB2 (2018 FIGO) cervical cancer…
- Conditions
- Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Radical Hysterectomy, Extrafascial Hysterectomy
- Trial name
- NCT06289751
- Testing
- Cadonilimab, Paclitaxel-albumin, Cisplatin
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Tongji Hospital
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC)
Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer
In this study, participants will be randomly assigned to either the experimental group or the control group. The experimental group will first receive SBRT (6Gy*3 fractions) to treat the primary tumor and metastatic lymph nodes.
- Conditions
- Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC), Stereotactic Body Radiation Therapy (SBRT)
- Trial name
- NCT06861712
- Testing
- SBRT, Docetaxel, Cisplatin, Toripalimab, Radical resection surgery
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer Stage ⅢA, Non-small Cell Lung Cancer Stage IIIB
Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer
to explore the impact of preoperative neoadjuvant immunotherapy on perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world
- Trial name
- NCT06394427
- Testing
- cycles of neoadjuvant therapy and duration of waiting for surgery
- Volunteers
- 250 people
- Sponsor
- West China Hospital
Triple Negative Breast Cancer
Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine (PCV) strategy with or without CD8-selective IL-2 mutein fusion protein in patients with triple negative…
- Trial name
- NCT07300475
- Testing
- Paclitaxel, Carboplatin, Pembrolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
Pleural Epithelioid Mesothelioma, Mesothelioma; Pleura
NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study
The goal of this clinical trial is to evaluate whether a combination of chemotherapy and immunotherapy can make surgery possible in adults with inoperable pleural mesothelioma (a type of cancer affecting the lung lining).
- Conditions
- Pleural Epithelioid Mesothelioma, Mesothelioma; Pleura, Neoadjuvant Chemoimmunotherapy
- Trial name
- NECIM (NCT07121374)
- Testing
- Neoadjuvant chemo-immunotherapy, Extended pleurectomy/decortication in case of reaching operability
- Where
- Belgium
- Volunteers
- 37 people
- Sponsor
- University Hospital, Antwerp
Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes
A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
This study tests a new treatment approach for people with early-stage triple negative breast cancer whose tumors have a high number of immune cells, called tumor-infiltrating lymphocytes or TILs, as seen by a pathologist on…
- Trial name
- NeoTILs (NCT07743190)
- Testing
- Carboplatin, Paclitaxcel, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Medical University of South Carolina
Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms
Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC
This phase II study evaluates the efficacy and safety of neoadjuvant chemoimmunotherapy consisting of camrelizumab (PD-1 inhibitor), paclitaxel, and carboplatin in patients with resectable locally advanced (Stage III-IVA)…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Oral Cavity Neoplasm
- Trial name
- NeoCamre-HN (NCT07400094)
- Testing
- Camrelizumab, Paclitaxel, carboplatin
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
Resectable/Potentially Resectable NSCLC
The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLC
This is a prospective, observational, multicenter real-world study aiming to investigate the efficacy and safety of NSCLC patients with or without adjuvant immunotherapy who have achieved pathologic complete remission after…
- Trial name
- NCT06243679
- Testing
- Immunotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xiangya Hospital of Central South University
Neoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection
Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
The goal of this observational study is to learn whether tumor and nodal downstaging after neoadjuvant chemo-immunotherapy is associated with better surgical outcomes in patients with clinical stage IIB-III non-small cell lung…
- Conditions
- Neoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection, Stage IIB-III NSCLC
- Trial name
- DRAGON-NSCLC (NCT07528066)
- Testing
- Robotic-assisted surgery (RATS)
- Where
- 10 sites in China, France and 1 more
- Volunteers
- 200 people
- Sponsor
- Shanghai Chest Hospital
Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
Previous studies confirmed locally advanced oral/oropharyngeal squamous cell carcinoma (LA OSCC or OPSCC) patients with a pathological response had higher probability of survival in neoadjuvant settings.
- Trial name
- NCT06009861
- Testing
- Tislelizumab, Albumin-Bound Paclitaxel, Cisplatin
- Where
- 13 sites in China
- Volunteers
- 110 people
- Sponsor
- Peking University Hospital of Stomatology
Esophageal Cancer, Immunotherapy
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
Although unprecedented advances have been made in the field of esophageal cancer in recent decades, the prognosis for patients with locally advanced esophageal squamous cell carcinoma (ESCC) remains extremely poor, accounting for…
- Conditions
- Esophageal Cancer, Immunotherapy, Induction Therapy, Chemoradiotherapy
- Trial name
- NCT06421376
- Testing
- Cardonilizumab, Chemoradiotherapy ±immunotherapy, Radical surgery
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colon Cancer (Stage II &Amp; III), Immunotherapy
Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study
The goal of this prospective, single-center, multi-cohort clinical trial is to evaluate the efficacy and safety of neoadjuvant Iparomlimab/Tuvonralimab combined with CAPEOX, with or without propranolol, in patients with locally…
- Conditions
- Colon Cancer (Stage II &Amp; III), Immunotherapy, Beta Blocker, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT07549906
- Testing
- Iparomlimab/Tuvonralimab, Capecitabine, Oxaliplatin
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Triple Negative Breast Cancer
Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial
Italian, multicenter, open-label, two-arm, comparative, randomized phase II study investigating if the addition of the experimental metabolic intervention consisting in cycles of Fasting-Like Approach, as administered every three…
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, Dietary Exposure, Fasting
- Trial name
- BREAKFAST-2 (NCT05763992)
- Testing
- Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)
- Where
- Italy
- Volunteers
- 145 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
The purpose of this study is to analyze esophageal cancer patients who underwent neoadjuvant immunotherapy with chemotherapy followed by esophagectomy to determine whether additional adjuvant therapy is associated with improved…
- Conditions
- Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy
- Trial name
- NCT06056336
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Guo Xufeng
Breast Cancer (Triple Negative Breast Cancer (TNBC))
Performance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer
The goal of this observational, retrospective, non interventional study is to learn about the efficacy of an Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer (TNBC).
- Trial name
- NEO-AgeTN (NCT07687446)
- Testing
- Non interventional study
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cervical Cancer, Locally Advanced Cervical Cancer
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
This is a multicenter, prospective, single-arm, phase 2 clinical trial designed to evaluate the therapeutic efficacy of the NACI (neoadjuvant chemotherapy plus Camrelizumab) for PD-L1-negative locally advanced cervical cancer.
- Conditions
- Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT06288360
- Testing
- Camrelizumab, Paclitaxel-albumin, Cisplatin
- Where
- 12 sites in China
- Volunteers
- 40 people
- Sponsor
- Tongji Hospital
Tumor Microenvironment, Lung Squamous Cell Carcinoma
Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma
To explore mechanisms of immunotherapy resistance and relation to changes in the TME before and after PD-1 blockade combined with chemotherapy
- Conditions
- Tumor Microenvironment, Lung Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT06436040
- Testing
- Pathological response assessment
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tang-Du Hospital
Cervical Cancer, Locally Advanced Cervical Cancer
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
It is a prospective, open-label, randomized, controlled phase II/III clinical trial in which patients with PD-L1-positive FIGO stage IB3, IIA2 and IIB（tumors >4 cm in diameter）will be enrolled and randomly divided into the…
- Conditions
- Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT06288373
- Testing
- Camrelizumab, Cisplatin, Nab paclitaxel
- Where
- 12 sites in China
- Volunteers
- 440 people
- Sponsor
- Tongji Hospital